Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Epcoritamab

Review the clinical trials studying epcoritamab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-24 of 24

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Status: Active
Location: 14 locations
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Status: Active
Location: 9 locations
Epcoritamab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma
Status: Active
Location: 8 locations
Epcoritamab with Lenalidomide and Tafasitamab for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, The ECLAT Trial
Status: Active
Location: 7 locations
A Study of Epcoritamab and Ibrutinib in People With Relapsed or Refractory Central Nervous System Lymphoma (CNSL)
Status: Active
Location: 7 locations
Rituximab and Epcoritamab for the Treatment of Follicular Lymphoma
Status: Active
Location: 6 locations
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients not in Complete Remission after CD19-directed CAR-T Therapy
Status: Active
Location: 5 locations
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Status: Active
Location: 4 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Status: Active
Location: 4 locations
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Location: 3 locations
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Active
Location: 2 locations
Epcoritamab for the Treatment of Previously Treated Waldenstrom Macroglobulinemia
Status: Active
Location: 2 locations
Epcoritamab, Zanubrutinib, and Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma
Status: Active
Location: 2 locations
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
Status: Active
Location: 2 locations
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Status: Active
Location: 2 locations
Epcoritamab for the Treatment of Non-Transplant Eligible Relapsed/Refractory Large B-Cell Lymphoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Epcoritamab and Lenalidomide in Treating Patients with Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Epcoritamab for the Treatment of Stage III-IV, Grade 1-3A Follicular Lymphoma not Accomplishing a Complete Response with Upfront Chemoimmunotherapy
Status: Active
Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Epcoritamab Before and After CAR T-cell Therapy for the Treatment of Patients with Relapsed or Refractory Large B-cell Lymphomas
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Epcoritamab in Combination with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-miniCVP) for Older, Unfit and Frail Patients or Anthracycline-Ineligible Patients with Diffuse Large B-Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Epcoritamab plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Epcoritamab with Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Siltuximab Prior to Epcoritamab for the Prevention of Cytokine Release Syndrome in Patients with Recurrent or Refractory Non-Hodgkin Lymphoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio